Author

Manuel Barreiro de Acosta 1

1 Complejo Universitario de Santiago de Compostela,Santiago de Compostela,Spain

Defining meaningful attributes for the treatment of IBD from patients' perspective

Edouard Louis, Juan Manuel Ramos-Goñi, Jesus Cuervo, Uri Kopylov, Manuel Barreiro de Acosta, Sara Mccartney, Greg Rosenfeld, Dominik Bettenworth, Ailsa L Hart, Kerri L. Novak, Xavier Donnet, David Easton, Roberto Saldana, Katja Protze, Eyal Tzur, Gabriela Alperovich, Francesc Casellas Jorda

DO PSEUDOPOLYPS INCREASE FECAL CALPROTECTIN IN PATIENTS WITH ULCERATIVE COLITIS IN CLINICAL AND ENDOSCOPIC REMISSION?

Cristina Calviño Suarez, Manuel Barreiro de Acosta, Violeta Mauriz-Barreiro, Iria Baston-Rey, Daniel de la Iglesia-Garcia, Rocío Ferreiro-Iglesias, J. Enrique Dominguez-Munoz

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Ahmad Albshesh, Joshua Taylor, Edoardo Vincenzo Savarino, Marie Truyens, Alessandro Armuzzi, Davide Giuseppe Ribaldone, Ariella Shitrit, Morine Fibelman, Pauliina Molander, Claire Liefferinckx, Stephane Nancy, Mohamed Korani, Klaudia Farkas, Manuel Barreiro de Acosta, Viktor Domislovic, Gerard Surís, Carl Eriksson, Catarin

EFFICACY AND SAFETY OF RE-INDUCTION WITH INTRAVENOUS USTEKINUMAB IN PATIENTS WITH CROHN´S DISEASE AND LOSS OF RESPONSE TO THAT DRUG

Fernando Bermejo, Laura Jiménez Márquez, Alicia Algaba, Olga Merino Ochoa, Luigi Melcarne, Iago Rodríguez-Lago, Milagros Vela Gonzalez, Manuel Barreiro de Acosta, Marta Carrillo, Alicia Lopez Garcia, Pilar López Serrano, Francisco Mesonero, Daniel Bonillo, Ivan Guerra

INFLUENCE OF THE INTERVAL OF TIME BETWEEN ANTI-TNF AND VEDOLIZUMAB OR USTEKINUMAB IN THE RESPONSE TO TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Iria Baston-Rey, Manuel Barreiro de Acosta, Marta Costa, Cristina Calviño Suarez, Violeta Mauriz-Barreiro, Daniel de la Iglesia-Garcia, Jaime González, Rocío Ferreiro-Iglesias, J. Enrique Dominguez-Munoz

Real life experience of first line anti-TNF in Crohn´s disease patients in Spain: do we have data to choose between infliximab and adalimumab?

Ignacio Marín-Jiménez, Guillermo Bastida, Ana Fores, Federico Argüelles-Arias, Ignacio Tagarro, Alonso Fernandez, Carmen Montoto Otero, Mariam Aguas, Rocio Ferreiro Iglesias, Olga Merino, Javier Santos Fernandez, Xavier Cortés, Francisco Mesonero Gismero, Manuel Barreiro de Acosta

RESCUE THERAPY WITH ANTI-TNF AGENTS FOR ESTABLISHED POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE. A MULTICENTRE, RETROSPECTIVE, NATIONWIDE STUDY

Eugeni Domenech Morral, Fiorella Cañete, Miriam Mañosa, Ramiro Cruz Gonzalez Sueyro, Sabino Riestra Menéndez, Manuel Barreiro de Acosta, Pilar Nos, Eva Iglesias Flores, Ana Gutierrez Casbas, Raquel Ríos, Luis Bujanda Fernández de Piérola, Carlos Gonzalez Muñoza, Albert Villoria, María José Casanova González, Antonio García He

RISK OF PROGRESSION OF PRECLINICAL ULCERATIVE COLITIS

Iago Rodríguez-Lago, Olga Merino, Irene Azagra, Ainara Maiz, Eva M. Zapata, Rebeca Higuera, Isabel Montalvo, María Fernández-Calderón, Paz Arreba, Juan Carrascosa Gil, Ainara Iriarte, Miguel Muñoz Navas, Jose Luis Cabriada, Manuel Barreiro de Acosta

THE JAK-3 AND TYK-2 / STAT PATHWAYS ARE ACTIVATED IN MODERATE TO SEVERE ULCERATIVE COLITIS

Manuel Barreiro de Acosta

THE JAK-3 AND TYK-2 / STAT PATHWAYS ARE ACTIVATED IN MODERATE TO SEVERE ULCERATIVE COLITIS

Manuel Barreiro de Acosta, Mabel Loza, Jose Manuel Brea, Cristina Calviño Suarez, Iria Baston-Rey, Rocío Ferreiro-Iglesias, J. Enrique Dominguez-Munoz

Item 1 - 10 / 10
1